Abstract
To assess the efficacy of ciprofloxacin in neutropenic patients, we conducted a randomized prospective trial comparing the combination of ciprofloxacin and netilmicin against piperacillin plus netilmicin as an empiric treatment of fever in cancer patients with neutropenia. Of 214 evaluable episodes, 115 and 99 were randomly assigned to the ciprofloxacin and the piperacillin arms, respectively. The overall response rates were very similar (59 and 62% for the ciprofloxacin and piperacillin arms, respectively). The response for the gram-positive bacteremias was almost identical (around 40%); this low response was due in part to an outbreak of infection by a multiply resistant strain of Staphylococcus epidermidis (for which the ciprofloxacin MIC was greater than or equal to 128 micrograms/ml) which occurred during the second half of the trial. Among gram-negative bacteremias, 9 of 11 infections (82%) responded to the ciprofloxacin combination compared with 3 of 7 (43%) that responded to the piperacillin combination (P = 0.23). The incidences of persistent, profound neutropenia were comparable in both treatments, but the susceptibility of the gram-negative organism to ciprofloxacin and netilmicin was significantly higher than was susceptibility to the other combination. Ciprofloxacin was well tolerated, and patients were able to convert from intravenous to oral therapy in 64 of 115 episodes.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodey G. P. Infection in cancer patients. A continuing association. Am J Med. 1986 Jul 28;81(1A):11–26. doi: 10.1016/0002-9343(86)90510-3. [DOI] [PubMed] [Google Scholar]
- De Jongh C. A., Joshi J. H., Newman K. A., Moody M. R., Wharton R., Standiford H. C., Schimpff S. C. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):96–100. [PubMed] [Google Scholar]
- Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Garlando F., Täuber M. G., Joos B., Oelz O., Lüthy R. Ciprofloxacin-induced hematuria. Infection. 1985 Jul-Aug;13(4):177–178. doi: 10.1007/BF01642807. [DOI] [PubMed] [Google Scholar]
- Klastersky J. Management of infection in granulocytopenic patients. J Antimicrob Chemother. 1983 Aug;12(2):102–104. doi: 10.1093/jac/12.2.102. [DOI] [PubMed] [Google Scholar]
- Maesen F. P., Teengs J. P., Baur C., Davies B. I. Quinolones and raised plasma concentrations of theophylline. Lancet. 1984 Sep 1;2(8401):530–530. doi: 10.1016/s0140-6736(84)92617-5. [DOI] [PubMed] [Google Scholar]
- Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
- Pizzo P. A., Robichaud K. J., Gill F. A., Witebsky F. G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982 Jan;72(1):101–111. doi: 10.1016/0002-9343(82)90594-0. [DOI] [PubMed] [Google Scholar]
- Reeves D. S., Bywater M. J., Holt H. A., White L. O. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984 Apr;13(4):333–346. doi: 10.1093/jac/13.4.333. [DOI] [PubMed] [Google Scholar]
- Smith G. M., Leyland M. J., Farrell I. D., Geddes A. M. A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother. 1988 May;21(5):647–655. doi: 10.1093/jac/21.5.647. [DOI] [PubMed] [Google Scholar]